Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, discusses a study that explored methylation as a predictor for response in ovarian cancer.
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
July 22nd 2024An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.
Read More